Over the past year, many different pharmaceuticals have been an ideal place for investors to hide. With increasing demand for several key drugs among baby boomers, retirees and overseas patients, countless investors are wondering if now is the time to go aggressively into this sector.
IN PICTURES: Eight Ways To Survive A Market Downturn

Pharmaceutical Demand Expected To Increase
Part of the reason for the surge in demand is that many developed Western nations have aging populations. In addition, China and other developing nations are increasing their demand for popular drugs on the market. According to The Freedonia Group, growth for many of these best-selling Western drugs is expected to increase by 13.6% this year in China alone. This, along with increasing demand worldwide, is causing many of the large drug manufacturers to report better than expected numbers during one of the worst recessions the world has seen in 25 years. (For more, see Stocks On Drugs: What It Takes To Get High.)

Ways To Make Money Off This Increasing Demand
You can make money off this promising sector in many ways. The following stocks offer potential long-term growth in addition to improving earnings:

Eli Lilly and Co. (NYSE:LLY) reported better than expected earnings of $1.20 per share compared to 97 cents at this time last year. Chairman and CEO John C. Lechleiter said, "Despite the downturn in the economy, in the first quarter of 2009 Lilly delivered strong financial results with good underlying operational performance, aided in part by movements in exchange rates. Our revenue growth included solid volume-based gains, while our gross margin percentage benefited from a stronger U.S. dollar. These results, in combination with prudent expense management, helped us to achieve operating leverage and robust earnings per share growth." In spite of the global economic recession, the company continues to report higher drug sales and profits as a result of strong demand. (For further reading, see Measuring The Medicine Makers.)

Gilead Sciences (Nasdaq:GILD) announced better than expected earnings of 63 cents, compared to 53 cents one year ago. Gilead also reported strong sales of its popular AIDS drugs, Atripla and Truvada, saying that both had increases of 28% and 23% compared to one year ago due to continually increasing worldwide sales. This will more than likely continue to help improve the company's overall earnings in the coming quarters.

Biogen Idec (Nasdaq:BIIB) reported earnings of $1.05 compared to 83 cents in the same quarter last year. As President and CEO James C. Mullen said, "Revenue growth from all three of our marketed products and continued advancement of our robust pipeline during the quarter were in line with our expectations. The expansion of our global footprint in recent years is serving us well, particularly in the current environment. One-third of our sales currently come from outside the United States, a clear illustration of our success in capturing the greatest amount of value for our products worldwide."

Demand for the company's three main drugs remains strong both inside and outside the U.S. This strong demand and improving year-over-year earnings results indicate the company's financial strength.

Sepracor (Nasdaq:SEPR) announced better than expected earnings of 31 cents per share compared to 6 cents last year. The company reiterated its guidance for all of 2009, saying that earnings will come in the $2.10 to $2.70 per share range. As President and CEO Adrian Adams said, "We delivered strong first-quarter results with robust EPS growth and are determined to continue to deliver strong financial performance." Sepracor continues to deliver strong year-over-year results and expects to keep up this pace for the foreseeable future. (For related reading, see Investing In The Healthcare Sector.)

Bottom Line
Even with the current recession hurting many different industries and companies, the pharmaceutical sector continues to show strong year-over-year earnings results and demand worldwide. While you never can be certain of what the future will bring, clearly Eli Lilly, Gilead Sciences, Biogen Idec and Sepracor all have improving earnings and strong momentum that should provide continued earnings growth - something that is difficult to find during this challenging economic environment.

Related Articles
  1. Stock Analysis

    3 Stocks that Are Top Bets for Retirement

    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  2. Investing News

    Are Stocks Cheap Now? Nope. And Here's Why

    Are stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
  3. Investing News

    4 Value Stocks Worth Your Immediate Attention

    Here are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
  4. Investing News

    These 3 High-Quality Stocks Are Dividend Royalty

    Here are three resilient, dividend-paying companies that may mitigate some worry in an uncertain investing environment.
  5. Stock Analysis

    An Auto Stock Alternative to Ford and GM

    If you're not sure where Ford and General Motors are going, you might want to look at this auto investment option instead.
  6. Mutual Funds & ETFs

    The 4 Best Buy-and-Hold ETFs

    Explore detailed analyses of the top buy-and-hold exchange traded funds, and learn about their characteristics, statistics and suitability.
  7. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  8. Investing News

    Ferrari’s IPO: Ready to Roll or Poor Timing?

    Will Ferrari's shares move fast off the line only to sputter later?
  9. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  10. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  1. What are the risks of annuities in a recession?

    Annuities come in several forms, the two most common being fixed annuities and variable annuities. During a recession, variable ... Read Full Answer >>
  2. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  3. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  6. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!